Our COVID19 phase 2 clinical trial for our lead product, rhu-pGSN, has begun.

Po-Shun Lee, MD

Po-Shun Lee is pulmonary and critical care physician who worked in Dr. Stossel’s lab for 10 years and conducted rhu-pGSN in preclinical animal models. Dr. Lee has presented at the American Thoracic Society International Meeting on the subject of pGSN’s clinical and scientific implications. In 2004, Dr. Lee received an award from the New England Respiratory Research Competition and Awards program for his research on pGSN.

Dr. Lee served as Chief Medical Officer and Senior Vice President, Clinical Development at Proteostasis Therapeutics. Prior to joining Proteostasis, Dr. Lee was Translational Medical Expert at Novartis Institute for Biomedical Research and Associate Medical Director at Vertex Pharmaceuticals, where he worked on phase 2 and phase 3 studies developing Vertex’ products for cystic fibrosis. Previously, Dr. Lee was an Instructor in Medicine at Harvard Medical School, attending pulmonologist/intensivist in the Pulmonary and Critical Care Division and the Medical Director for the Pulmonary Function Lab at the Brigham & Women’s Hospital.

Dr. Lee received his undergraduate degree from Johns Hopkins University and his medical degree from the University of Pennsylvania School of Medicine. He completed his residency training at the Brown University Internal Medicine Residency Program and his subspecialty training at the Harvard Combined Pulmonary and Critical Care Fellowship.